Related Experiment Videos
In vitro susceptibility of Cryptococcus neoformans isolates from patients with acquired immunodeficiency syndrome
M Poon1, D C Cronin, G P Wormser
1Department of Microbiology, Mount Sinai Medical Center, New York, NY 10029-6574.
Abstract:
Cryptococcus neoformans strains from 26 individual patients with acquired immunodeficiency syndrome (AIDS) and three isolates from patients without AIDS were tested for their susceptibility to amphotericin B, flucytosine, ketoconazole, and miconazole nitrate. Ninety percent of the C neoformans isolates from patients with AIDS were inhibited by drug concentrations within achievable serum levels. The minimum fungicidal concentration of the four tested antifungal agents, however, exceeded obtainable cerebrospinal fluid levels.
Insights
This study evaluated antifungal drug susceptibility in Cryptococcus neoformans from AIDS patients. While most strains were inhibited by achievable serum drug levels, fungicidal concentrations exceeded cerebrospinal fluid levels.
Area of Science:
- Mycology
- Infectious Diseases
- Pharmacology
Background:
- Cryptococcus neoformans is an opportunistic fungal pathogen.
- Acquired immunodeficiency syndrome (AIDS) increases susceptibility to cryptococcal infections.
- Antifungal drug resistance is a growing concern in managing cryptococcosis.
Purpose of the Study:
- To assess the in vitro susceptibility of Cryptococcus neoformans isolates from AIDS patients to four antifungal agents.
- To compare drug susceptibility profiles between isolates from patients with and without AIDS.
- To determine if achievable drug concentrations in serum and cerebrospinal fluid (CSF) are effective against these isolates.
Main Methods:
- Susceptibility testing of Cryptococcus neoformans isolates.
- Testing against amphotericin B, flucytosine, ketoconazole, and miconazole nitrate.
- Evaluation of drug concentrations relevant to serum and cerebrospinal fluid levels.
Main Results:
- Ninety percent of Cryptococcus neoformans isolates from AIDS patients showed inhibition by achievable serum drug concentrations.
- All tested antifungal agents demonstrated minimum fungicidal concentrations that exceeded obtainable cerebrospinal fluid levels.
- Isolates from non-AIDS patients were also tested, providing a comparative baseline.
Conclusions:
- Standard antifungal therapies may achieve inhibitory serum levels for Cryptococcus neoformans in AIDS patients.
- Cerebrospinal fluid drug levels may be insufficient to eradicate cryptococcal infections in the CNS.
- Further research into optimizing antifungal strategies for CNS cryptococcosis is warranted.